Compare MBBC & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBBC | MIRA |
|---|---|---|
| Founded | 1902 | 2020 |
| Country | United States | United States |
| Employees | 35 | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.1M | 37.1M |
| IPO Year | N/A | 2023 |
| Metric | MBBC | MIRA |
|---|---|---|
| Price | $15.10 | $0.74 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.0K | ★ 86.0K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $47.11 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.02 | $0.60 |
| 52 Week High | $15.79 | $2.45 |
| Indicator | MBBC | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 53.82 | 29.81 |
| Support Level | $14.63 | N/A |
| Resistance Level | $15.48 | $1.02 |
| Average True Range (ATR) | 0.16 | 0.08 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 75.86 | 21.38 |
Marathon Bancorp Inc is a mid-tier holding company for Marathon Bank, a Wisconsin-chartered savings bank. The group operates as a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the group's revenue comes from interest income on loans and debt securities.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.